Peer-reviewed veterinary case report
Chemoembolization treatment for liver cancer in dogs
By Rogatko, Cleo P et al.·Published in Journal of veterinary internal medicine·2021·The Animal Medical Center, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Drug-eluting bead chemoembolization for the treatment of nonresectable hepatic carcinoma in dogs: A prospective clinical trial.
- Species:
- dog
Plain-English summary
A group of 16 dogs with nonresectable liver cancer (hepatic carcinoma) underwent a treatment called drug-eluting bead transarterial chemoembolization (DEB-TACE) to see if it could help shrink their tumors. After about 12 weeks, most dogs showed stable disease or partial improvement, with some experiencing mild side effects. However, a few dogs faced serious complications, and unfortunately, two dogs died as a result of the treatment. On average, the dogs lived for about 337 days after the procedure, but those who had lost weight before treatment had a shorter survival time. Overall, DEB-TACE appears to be a promising option for treating this type of cancer in dogs.
People also search for: dog liver cancer treatment · chemoembolization for dogs · dog weight loss cancer · liver tumor in dogs prognosis
Abstract
BACKGROUND: Effective treatment options for nonresectable hepatic carcinoma (HC) in dogs are limited. HYPOTHESIS/OBJECTIVE: Objectives were to report outcomes, complications, and tumor responses via computed tomography (CT) assessment after drug-eluting bead transarterial chemoembolization (DEB-TACE) for nonresectable HC in dogs. The authors hypothesized that major complications would be uncommon and short-term CT assessment would demonstrate stable disease or partial response. ANIMALS: Client-owned dogs (n = 16) with nonresectable HC. METHODS: Prospective, single-arm clinical trial. Drug-eluting bead transarterial chemoembolization was performed to varying levels of blood flow stasis. Computed tomography imaging was compared before and approximately 12 weeks after initial treatment. RESULTS: Drug-eluting bead transarterial chemoembolization was successfully administered in all attempts. Based on percent change in elliptical tumor volume response (mL), stable disease (8/13; 62%) was the most common outcome followed by partial response (3/13; 23%) and progressive disease (2/13; 15%) with a median of 74 days (range, 39-125) after initial treatment. Median tumor volume (mL) after DEB-TACE decreased in volume by 13% (range, 56% decrease to 77% increase). Mild complications consistent with postembolization syndrome occurred after 7/27 (26%) treatments. Major complications occurred after 3/27 (11%) treatments: hepatic abscess/septicemia (2) and cholecystitis/death (1), resulting in treatment-induced death after 2/27 (7%) treatments. Median survival time after treatment was 337 days (range, 22-1061). Dogs with a presenting complaint of weight loss (P = .02) had a significantly shorter median survival time (126 days; range, 46-337) than those dogs without prior history of weight loss (582 days; range, 22-1061). CONCLUSIONS: Drug-eluting bead transarterial chemoembolization for nonresectable HC is a feasible procedure, which promoted stable disease or partial response in 85% of dogs in this study sample.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33955600/